Press Releases Archives | Page 24 of 119

I Peace announces new iPSC lines to reduce immune rejection risk for U.S. population

October 30, 2024 By Cade Hildreth, Founder & President Leave a Comment

More than 100 million people in the U.S. have this HLA-A haplotype

October 30, 2024, Palo Alto, CA – Leading G.M.P. cell CDMO I Peace, Inc., specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the company has successfully generated iPS cell lines that are homozygous for HLA A, C, and DPA1. Two clonal lines are available for cell therapy developers and pharmaceutical companies as off-the-shelf products in both G.M.P. and research-grade. [Read more…]

Nucleus Biologics Launches NB-KUL™ DF: A DMSO-Free, Chemically-Defined Cryomedia Revolutionizing Cell and Gene Therapy Cryopreservation

October 17, 2024 By Cade Hildreth, Founder & President Leave a Comment

San Diego, CA, October 15, 2024 – Nucleus Biologics, a leading provider of cell culture and bioprocessing solutions for the cell and gene therapy (CGT) industry, has launched NB-KUL DF, a DMSO-free, chemically-defined cryomedia set to redefine cryopreservation standards. Designed for CGT manufacturers, NB-KUL DF matches DMSO-based media performance and outperforms other DMSO-free options in cell viability, recovery, and expansion. While DMSO is an effective cryoprotectant, its toxicity compromises cell viability, can cause patient issues, and requires complex wash steps, adding cost and variability. NB-KUL DF eliminates these issues, offering a DMSO-free solution that preserves cell integrity, eliminates the potential for patient side effects, and simplifies cryopreservation making it ideal for T cells, MSCs, and other sensitive cell types used in CGT. [Read more…]

AABB Releases New Resources and Initiatives For its Certified Advanced Biotherapies Professional (CABP) Program

October 16, 2024 By Cade Hildreth, Founder & President Leave a Comment

Oct 11, 2024, Bethesda, MD – The Association for the Advancement of Blood & Biotherapies (AABB) is pleased to announce several new offerings as part of its Certified Advanced Biotherapies Professional (CABP) credentialing program. These updates, released to make the CABP program more accessible to biotherapies professionals and organizations, include:

• CABP Exam Prep Bootcamps Video Series [Read more…]

PeptiGrowth Inc. is Launching a Novel Synthetic FGF2 Alternative Peptide (FGFR1c Agonist)

October 10, 2024 By Cade Hildreth, Founder & President Leave a Comment

PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo; President: Jiro Sugimoto) has successfully developed a novel synthetic peptide called “FGF2 alternative peptide (FGFR1c agonist)”, which has equivalent function to recombinant FGF2 (Fibroblast Growth Factor 2, basic FGF (bFGF)). This product will be on the market at the beginning of October 2024. [Read more…]

Cell X Technologies and Aspen Neuroscience collaborate to address throughput and scalability in manufacturing automation to facilitate iPSC cell processing

October 10, 2024 By Cade Hildreth, Founder & President Leave a Comment

Advancing the promise of cell-replacement therapy for people with Parkinson’s disease

CLEVELAND, Ohio / SAN DIEGO, Calif. – October 8, 2024 – Cell X Technologies, pioneers in automated cell processing solutions, and Aspen Neuroscience, Inc., dedicated to autologous regenerative medicine, have entered into a collaboration and licensing agreement focused on providing an automated solution for Aspen’s iPSC-derived autologous clinical manufacturing. [Read more…]